In vitro 3D cancer spheroids (tumoroids) exhibit a drug resistance profile similar to that found in solid tumors. 3D spheroid culture methods recreate more physiologically relevant microenvironments for cells. Therefore, these models are more appropriate for cancer drug screening. We have recently developed a protocol for MCF-7 cell spheroid culture, and used this method to test the effects of different types of drugs on this estrogen-dependent breast cancer cell spheroid. Our results demonstrated that MCF-7 cells can grow spheroid in medium using a low attachment plate. We managed to grow one spheroid in each well, and the spheroid can grow over a month, the size of the spheroid can grow over a hundred times in volume. Our targeted drug experimental results suggest that estrogen sulfotransferase, steroid sulfatase, and G protein-coupled estrogen receptor may play critical roles in MCF-7 cell spheroid growth, while estrogen receptors α and β may not play an essential role in MCF-7 spheroid growth. Organoids are the miniatures of in vivo tissues and reiterate the in vivo microenvironment of a specific organ, best fit for the in vitro studies of diseases and drug development. Tumoroid, developed from cancer cell lines or patients’ tumor tissue, is the best in vitro model of in vivo tumors. 3D spheroid technology will be the best future method for drug development of cancers and other diseases. Our reported method can be developed clinically to develop personalized drugs when the patient’s tumor tissues are used to develop a spheroid culture for drug screening.
KeywordsMCF-7 CellSpheroid Culture3D Cell CultureEstrogen-Dependent Breast CancerCancer Drug DevelopmentPersonalized Cancer Drug Development
Salvo, E.M., Ramirez, A.O., Cueto, J., Law, E.H., Situ, A., Cameron, C. and Samjoo, I.A. (2021) Risk of Recurrence among Patients with HR-Positive, HER2-Negative, Early Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review and Meta-Analysis. Breast, 57, 5-17. https://doi.org/10.1016/j.breast.2021.02.009
O’Reilly, D., Sendi, M.A. and Kelly, C.M. (2021) Overview of Recent Advances in Metastatic Triple Negative Breast Cancer. World Journal of Clinical Oncology, 12, 164-182. https://doi.org/10.5306/wjco.v12.i3.164
Jia, S., Liu, Z., Zhang, J., Zhao, C., Zhu, L., Kong, J., Han, H., Shang, Y., Shen, D. and Duan, X. (2021) Can Internal Mammary Lymph Nodes Irradiation Bring Survival Benefits for Breast Cancer Patients? A Systematic Review and Meta-Analysis of 12,705 Patients in 12 Studies. Radiation Oncology, 16, 42. https://doi.org/10.1186/s13014-021-01772-y
Cipriano, é. and Mesquita, A. (2021) Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl), 15, 1-14. https://doi.org/10.1177/11782234211002491
Baber, R., Hickey, M. and Kwik, M. (2005) Therapy for Menopausal Symptoms during and after Treatment for Breast Cancer: Safety Considerations. Drug Safety, 28, 1085-1100. https://doi.org/10.2165/00002018-200528120-00004
Adhikari, N., Amin, S.A., Saha, A. and Jha, T. (2017) Combating Breast Cancer with Non-Steroidal Aromatase Inhibitors (NSAIs): Understanding the Chemico-Biological Interactions through Comparative SAR/QSAR Study. European Journal of Medicinal Chemistry, 137, 365-438. https://doi.org/10.1016/j.ejmech.2017.05.041
Ayan, D., Roy, J., Maltais, R. and Poirier, D. (2011) Impact of Estradiol Structural Modifications (18-Methyl and/or 17-Hydroxy Inversion of Configuration) on the in Vitro and in Vivo Estrogenic Activity. Journal of Steroid Biochemistry and Molecular Biology, 127, 324-330. https://doi.org/10.1016/j.jsbmb.2011.07.009
Biggar, R.J. (2012) Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications. Clinical Cancer Research, 18, 2133-2137. https://doi.org/10.1158/1078-0432.CCR-11-1389
Lord, R.S., Bongiovanni, B. and Bralley, J.A. (2002) Estrogen Metabolism and the Diet-Cancer Connection: Rationale for Assessing the Ratio of Urinary Hydroxylated Estrogen Metabolites. Alternative Medicine Review, 7, 112-129.
Kiyotani, K., Mushiroda, T., Nakamura, Y. and Zembutsu, H. (2011) Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters. Drug Metabolism and Pharmacokinetics, 27, 122-131. https://doi.org/10.2133/dmpk.DMPK-11-RV-084
Fleeman, N., Martin Saborido, C., Payne, K., Boland, A., Dickson, R., Dundar, Y., Fernandez Santander, A., Howell, S., Newman, W., Oyee, J. and Walley, T. (2011) The Clinical Effectiveness and Cost-Effectiveness of Genotyping for CYP2D6 for the Management of Women with Breast Cancer Treated with Tamoxifen: A Systematic Review. Health Technology Assessment, 15, 1-102. https://doi.org/10.3310/hta15330
Sasano, H., Nagasaki, S., Miki, Y. and Suzuki, T. (2009) New Developments in Intracrinology of Human Breast Cancer: Estrogen Sulfatase and Sulfotransferase. Annals of the New York Academy of Sciences, 1155, 76-79. https://doi.org/10.1111/j.1749-6632.2008.03683.x
Pasqualini, J.R. (2009) Breast Cancer and Steroid Metabolizing Enzymes: The Role of Progestogens. Maturitas, 65, S17-S21. https://doi.org/10.1016/j.maturitas.2009.11.006
Subramanian, A., Salhab, M. and Mokbel, K. (2008) Oestrogen Producing Enzymes and Mammary Carcinogenesis: A Review. Breast Cancer Research and Treatment, 111, 191-202. https://doi.org/10.1007/s10549-007-9788-0
Ito, K., Utsunomiya, H., Yaegashi, N. and Sasano, H. (2007) Biological Roles of Estrogen and Progesterone in Human Endometrial Carcinoma—New Developments in Potential Endocrine Therapy for Endometrial Cancer. Endocrine Journal, 54, 667-679. https://doi.org/10.1507/endocrj.KR-114
Ji, X.W., Chen, G.P., Song, Y., Hua, M., Wang, L.J., Li, L., Yuan, Y., Wang, S.Y., Zhou, T.Y. and Lu, W. (2015) Intratumoral Estrogen Sulfotransferase Induction Contributes to the Anti-Breast Cancer Effects of the Dithiocarbamate Derivative TM208. Acta Pharmaceutica Sinica, 36, 1246-1255. https://doi.org/10.1038/aps.2015.14
Russo, M., Cejas, C.M. and Pitingolo, G. (2022) Advances in Microfluidic 3D Cell Culture for Preclinical Drug Development. Progress in Molecular Biology and Translational Science, 187, 163-204. https://doi.org/10.1016/bs.pmbts.2021.07.022
Comşa, Ş., Cîmpean, A.M. and Raica, M. (2015) The Story of MCF-7 Breast Cancer Cell Line: 40 Years of Experience in Research. Anticancer Research, 35, 3147-3154.
Pulze, L., Congiu, T., Brevini, T.A.L., Grimaldi, A., Tettamanti, G., D’Antona, P., Baranzini, N., Acquati, F., Ferraro, F. and de Eguileor, M. (2020) MCF7 Spheroid Development: New Insight about Spatio/Temporal Arrangements of TNTs, Amyloid Fibrils, Cell Connections, and Cellular Bridges. International Journal of Molecular Sciences, 21, 5400. https://doi.org/10.3390/ijms21155400
Shi, D., Li, H., Zhang, Z., He, Y., Chen, M., Sun, L. and Zhao, P. (2022) Cryptotanshinone Inhibits Proliferation and Induces Apoptosis of Breast Cancer MCF-7 Cells via GPER Mediated PI3K/AKT Signaling Pathway. PLoS ONE, 17, e0262389. https://doi.org/10.1371/journal.pone.0262389
Batallán Burrowes, A.A., Sundarakrishnan, A., Bouhour, C. and Chapman, C.A. (2021) G Protein-Coupled Estrogen Receptor-1 Enhances Excitatory Synaptic Responses in the Entorhinal Cortex. Hippocampus, 31, 1191-1201. https://doi.org/10.1002/hipo.23383
Bansal, S. and Chopra, K. (2021) Selective ER-β Agonists Alleviate Neuronal Deficits in Insulin-Resistant Estrogen-Deficient Rats. Climacteric, 24, 415-420. https://doi.org/10.1080/13697137.2020.1857353
Wang, H., Brown, P.C., Chow, E.C.Y., Ewart, L., Ferguson, S.S., Fitzpatrick, S., Freedman, B.S., Guo, G.L., Hedrich, W., Heyward, S., Hickman, J., Isoherranen, N., Li, A.P., Liu, Q., Mumenthaler, S.M., Polli, J., Proctor, W.R., Ribeiro, A., Wang, J.Y., Wange, R.L. and Huang, S.M. (2021) 3D Cell Culture Models: Drug Pharmacokinetics, Safety Assessment, and Regulatory Consideration. Clinical and Translational Science, 14, 1659-1680. https://doi.org/10.1111/cts.13066
Park, Y., Huh, K.M. and Kang, S.W. (2021) Applications of Biomaterials in 3D Cell Culture and Contributions of 3D Cell Culture to Drug Development and Basic Biomedical Research. International Journal of Molecular Sciences, 22, 2491. https://doi.org/10.3390/ijms22052491
Slanař, O., Hronová, K., Bartošová, O. and Šíma, M. (2021) Recent Advances in the Personalized Treatment of Estrogen Receptor-Positive Breast Cancer with Tamoxifen: A Focus on Pharmacogenomics. Expert Opinion on Drug Metabolism & Toxicology, 17, 307-321. https://doi.org/10.1080/17425255.2021.1865310
Kumar, N., Gulati, H.K., Sharma, A., Heer, S., Jassal, A.K., Arora, L., Kaur, S., Singh, A., Bhagat, K., Kaur, A., Singh, H., Singh, J.V. and Bedi, P.M.S. (2021) Most Recent Strategies Targeting Estrogen Receptor Alpha for the Treatment of Breast Cancer. Molecular Diversity, 25, 603-624. https://doi.org/10.1007/s11030-020-10133-y
Khatpe, A.S., Adebayo, A.K., Herodotou, C.A., Kumar, B. and Nakshatri, H. (2021) Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer. Cancers (Basel), 13, 369. https://doi.org/10.3390/cancers13030369
Farcas, A.M., Nagarajan, S., Cosulich, S. and Carroll, J.S. (2021) Genome-Wide Estrogen Receptor Activity in Breast Cancer. Endocrinology, 162, bqaa224. https://doi.org/10.1210/endocr/bqaa224
Zhou, Y. and Liu, X. (2020) The Role of Estrogen Receptor Beta in Breast Cancer. Biomarker Research, 8, 39. https://doi.org/10.1186/s40364-020-00223-2
Sharma, G., Mauvais-Jarvis, F. and Prossnitz, E.R. (2018) Roles of G Protein-Coupled Estrogen Receptor GPER in Metabolic Regulation. The Journal of Steroid Biochemistry and Molecular Biology, 176, 31-37. https://doi.org/10.1016/j.jsbmb.2017.02.012
Pepermans, R.A., Sharma, G. and Prossnitz, E.R. (2021) G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives. Cells, 10, 672. https://doi.org/10.3390/cells10030672
Rouhimoghadam, M., Lu, A.S., Salem, A.K. and Filardo, E.J. (2020) Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function. Frontiers in Endocrinology (Lausanne), 11, Article ID: 591217. https://doi.org/10.3389/fendo.2020.591217
Hernández-Silva, C.D., Villegas-Pineda, J.C. and Pereira-Suárez, A.L. (2020) Expression and Role of the G Protein-Coupled Estrogen Receptor (GPR30/GPER) in the Development and Immune Response in Female Reproductive Cancers. Frontiers in Endocrinology (Lausanne), 11, Article No. 544. https://doi.org/10.3389/fendo.2020.00544
Xu, S., Yu, S., Dong, D. and Lee, L.T.O. (2019) G Protein-Coupled Estrogen Receptor: A Potential Therapeutic Target in Cancer. Frontiers in Endocrinology (Lausanne), 10, Article No. 725. https://doi.org/10.3389/fendo.2019.00725
Molina, L., Figueroa, C.D., Bhoola, K.D. and Ehrenfeld, P. (2017) GPER-1/GPR30 a Novel Estrogen Receptor Sited in the Cell Membrane: Therapeutic Coupling to Breast Cancer. Expert Opinion on Therapeutic Targets, 21, 755-766. https://doi.org/10.1080/14728222.2017.1350264
Tanwar, A.K., Dhiman, N., Kumar, A. and Jaitak, V. (2021) Engagement of Phytoestrogens in Breast Cancer Suppression: Structural Classification and Mechanistic Approach. European Journal of Medicinal Chemistry, 213, Article ID: 113037. https://doi.org/10.1016/j.ejmech.2020.113037
Engin, A.B. and Engin, A. (2021) The Effect of Environmental Bisphenol A Exposure on Breast Cancer Associated with Obesity. Environmental Toxicology and Pharmacology, 81, Article ID: 103544. https://doi.org/10.1016/j.etap.2020.103544
Anbar, H.S., Isa, Z., Elounais, J.J., Jameel, M.A., Zib, J.H., Samer, A.M., Jawad, A.F. and El-Gamal, M.I. (2021) Steroid Sulfatase Inhibitors: The Current Landscape. Expert Opinion on Therapeutic Patents, 31, 453-472. https://doi.org/10.1080/13543776.2021.1910237
Saha, T., Makar, S., Swetha, R., Gutti, G. and Singh, S.K. (2019) Estrogen Signaling: An Emanating Therapeutic Target for Breast Cancer Treatment. European Journal of Medicinal Chemistry, 177, 116-143. https://doi.org/10.1016/j.ejmech.2019.05.023
Israel, B.B., Tilghman, S.L., Parker-Lemieux, K. and Payton-Stewart, F. (2018) Phytochemicals: Current Strategies for Treating Breast Cancer. Oncology Letters, 15, 7471-7478. https://doi.org/10.3892/ol.2018.8304
Correia, A.S., Gärtner, F. and Vale, N. (2021) Drug Combination and Repurposing for Cancer Therapy: The Example of Breast Cancer. Heliyon, 7, e05948. https://doi.org/10.1016/j.heliyon.2021.e05948
Fisusi, F.A. and Akala, E.O. (2019) Drug Combinations in Breast Cancer Therapy. Pharmaceutical Nanotechnology, 7, 3-23. https://doi.org/10.2174/2211738507666190122111224